參考文獻 |
1. Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.
2. Kai‑Chi Tsai, S.J.H., Jen‑Hung Wang, Shyh‑Jer Huang, Chien‑Hsing Wang, Jiunn‑Tat Lee, Chia‑Yi Lee, Chung‑Hsing Chang, Cutaneous Malignant Melanoma in Eastern Taiwan: Clinicopathologic Analysis of 56 Cases. Dermatologica Sinica, 2019: p. 187-193.
3. 2021 Health Promotion Administration Annual Report. 2021: Health Promotion Administration Ministry of Health and Welfare, Taiwan.
4. Kaidbey, K.H., et al., Photoprotection by melanin--a comparison of black and Caucasian skin. J Am Acad Dermatol, 1979. 1(3): p. 249-60.
5. Shain, A.H. and B.C. Bastian, From melanocytes to melanomas. Nat Rev Cancer, 2016. 16(6): p. 345-58.
6. Bastian, B.C., The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol, 2014. 9: p. 239-71.
7. Jimbow, K., et al., Mitotic activity in non-neoplastic melanocytes in vivo as determined by histochemical, autoradiographic, and electron microscope studies. J Cell Biol, 1975. 66(3): p. 663-70.
8. Cui, R., et al., Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell, 2007. 128(5): p. 853-64.
9. Davis, L.E., S.C. Shalin, and A.J. Tackett, Current state of melanoma diagnosis and treatment. Cancer Biol Ther, 2019. 20(11): p. 1366-1379.
10. Rouzaud, F., et al., MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res, 2005. 571(1-2): p. 133-52.
11. Wenczl, E., et al., (Pheo)melanin photosensitizes UVA-induced DNA damage in cultured human melanocytes. J Invest Dermatol, 1998. 111(4): p. 678-82.
12. Hill, H.Z. and G.J. Hill, UVA, pheomelanin and the carcinogenesis of melanoma. Pigment Cell Res, 2000. 13 Suppl 8: p. 140-4.
13. Mitra, D., et al., An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature, 2012. 491(7424): p. 449-53.
14. Lee, C., et al., Historical review of melanoma treatment and outcomes. Clin Dermatol, 2013. 31(2): p. 141-7.
15. Rebecca, V.W., V.K. Sondak, and K.S. Smalley, A brief history of melanoma: from mummies to mutations. Melanoma Res, 2012. 22(2): p. 114-22.
16. Schadendorf, D., et al., Melanoma. The Lancet, 2018. 392(10151): p. 971-984.
17. Dickson, P.V. and J.E. Gershenwald, Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am, 2011. 20(1): p. 1-17.
18. Alexandrov, L.B., et al., Signatures of mutational processes in human cancer. Nature, 2013. 500(7463): p. 415-21.
19. Hodis, E., et al., A landscape of driver mutations in melanoma. Cell, 2012. 150(2): p. 251-63.
20. Huang, F.W., et al., Highly recurrent TERT promoter mutations in human melanoma. Science, 2013. 339(6122): p. 957-9.
21. Horn, S., et al., TERT promoter mutations in familial and sporadic melanoma. Science, 2013. 339(6122): p. 959-61.
22. Krauthammer, M., et al., Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet, 2012. 44(9): p. 1006-14.
23. Shain, A.H., et al., The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med, 2015. 373(20): p. 1926-36.
24. Dankort, D., et al., Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet, 2009. 41(5): p. 544-52.
25. Tsao, H., et al., Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol, 2004. 122(2): p. 337-41.
26. Cancer Genome Atlas, N., Genomic Classification of Cutaneous Melanoma. Cell, 2015. 161(7): p. 1681-96.
27. Long, G.V., et al., Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol, 2011. 29(10): p. 1239-46.
28. Menzies, A.M., et al., Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res, 2012. 18(12): p. 3242-9.
29. Janssen, C.S., et al., The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer, 2008. 99(10): p. 1673-7.
30. Wu, J., et al., Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol, 2007. 29(6): p. 534-7.
31. Yeh, I., A. von Deimling, and B.C. Bastian, Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst, 2013. 105(12): p. 917-9.
32. Patton, E.E., et al., BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol, 2005. 15(3): p. 249-54.
33. Ihle, M.A., et al., Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer, 2014. 14: p. 13.
34. Lovly, C.M., et al., Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One, 2012. 7(4): p. e35309.
35. Curtin, J.A., et al., Distinct sets of genetic alterations in melanoma. N Engl J Med, 2005. 353(20): p. 2135-47.
36. Krauthammer, M., et al., Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet, 2015. 47(9): p. 996-1002.
37. Munoz-Couselo, E., et al., NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther, 2017. 10: p. 3941-3947.
38. Maertens, O., et al., Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2013. 3(3): p. 338-49.
39. Heidenreich, B. and R. Kumar, TERT promoter mutations in telomere biology. Mutat Res Rev Mutat Res, 2017. 771: p. 15-31.
40. Shain, A.H. and J.R. Pollack, The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One, 2013. 8(1): p. e55119.
41. Mittal, P. and C.W.M. Roberts, The SWI/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol, 2020. 17(7): p. 435-448.
42. Sharpless, N.E. and R.A. DePinho, The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev, 1999. 9(1): p. 22-30.
43. Zhang, Y., Y. Xiong, and W.G. Yarbrough, ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 1998. 92(6): p. 725-34.
44. Hussussian, C.J., et al., Germline p16 mutations in familial melanoma. Nat Genet, 1994. 8(1): p. 15-21.
45. Recio, J.A., et al., Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res, 2002. 62(22): p. 6724-30.
46. Wu, H., V. Goel, and F.G. Haluska, PTEN signaling pathways in melanoma. Oncogene, 2003. 22(20): p. 3113-22.
47. You, M.J., et al., Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A, 2002. 99(3): p. 1455-60.
48. Schadendorf, D., et al., Melanoma. Nat Rev Dis Primers, 2015. 1: p. 15003.
49. Kim, R.H. and S.A. Meehan, Immunostain use in the diagnosis of melanomas referred to a tertiary medical center: a 15-year retrospective review (2001-2015). J Cutan Pathol, 2017. 44(3): p. 221-227.
50. Willis, B.C., et al., SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl Immunohistochem Mol Morphol, 2015. 23(2): p. 109-12.
51. Hudson, A.R. and B.R. Smoller, Immunohistochemistry in diagnostic dermatopathology. Dermatol Clin, 1999. 17(3): p. 667-89, x.
52. Skelton, H.G., 3rd, et al., HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation. Am J Dermatopathol, 1991. 13(6): p. 543-50.
53. Nielsen, P.S., R. Riber-Hansen, and T. Steiniche, Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J Dermatopathol, 2011. 33(4): p. 361-70.
54. Nasr, M.R. and O. El-Zammar, Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol, 2008. 30(2): p. 117-22.
55. Ivan, D. and V.G. Prieto, Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls. Future Oncol, 2010. 6(7): p. 1163-75.
56. Kucher, C., et al., Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol, 2004. 26(6): p. 452-7.
57. Bauer, J. and B.C. Bastian, Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther, 2006. 19(1): p. 40-9.
58. Gerami, P., et al., Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol, 2009. 33(8): p. 1146-56.
59. Luo, S., A. Sepehr, and H. Tsao, Spitz nevi and other Spitzoid lesions part I. Background and diagnoses. J Am Acad Dermatol, 2011. 65(6): p. 1073-84.
60. Gammon, B., et al., Enhanced detection of spitzoid melanomas using fluorescence in situ hybridization with 9p21 as an adjunctive probe. Am J Surg Pathol, 2012. 36(1): p. 81-8.
61. Domingues, B., et al., Melanoma treatment in review. Immunotargets Ther, 2018. 7: p. 35-49.
62. Kim, C., et al., Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist, 2010. 15(7): p. 765-71.
63. Hill, G.J., 2nd, E.T. Krementz, and H.Z. Hill, Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer, 1984. 53(6): p. 1299-305.
64. Middleton, M.R., et al., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol, 2000. 18(1): p. 158-66.
65. Chapman, P.B., et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011. 364(26): p. 2507-16.
66. Menzies, A.M., G.V. Long, and R. Murali, Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther, 2012. 6: p. 391-405.
67. Menzies, A.M. and G.V. Long, Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res, 2014. 20(8): p. 2035-43.
68. Eroglu, Z. and A. Ribas, Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol, 2016. 8(1): p. 48-56.
69. Ascierto, P.A., et al., Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol, 2016. 17(9): p. 1248-60.
70. Nguyen, M.T., et al., miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma. Biomolecules, 2021. 11(11).
71. Mansh, M., Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J Biol Med, 2011. 84(4): p. 381-9.
72. Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010. 363(8): p. 711-23.
73. Weiss, S.A., J.D. Wolchok, and M. Sznol, Immunotherapy of Melanoma: Facts and Hopes. Clin Cancer Res, 2019. 25(17): p. 5191-5201.
74. Herbst, R.S., et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014. 515(7528): p. 563-7.
75. Larkin, J., et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med, 2015. 373(1): p. 23-34.
76. Schachter, J., et al., Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 2017. 390(10105): p. 1853-1862.
77. Dummer, R., et al., Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med, 2021. 27(10): p. 1789-1796.
78. Bollag, G., et al., Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov, 2012. 11(11): p. 873-86.
79. Hauschild, A., et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012. 380(9839): p. 358-65.
80. Wagle, N., et al., MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov, 2014. 4(1): p. 61-8.
81. Long, G.V., et al., Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun, 2014. 5: p. 5694.
82. Shi, H., et al., Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov, 2014. 4(1): p. 80-93.
83. Shi, H., et al., Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun, 2012. 3: p. 724.
84. Poulikakos, P.I., et al., RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011. 480(7377): p. 387-90.
85. Nazarian, R., et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010. 468(7326): p. 973-7.
86. Emery, C.M., et al., MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A, 2009. 106(48): p. 20411-6.
87. Johannessen, C.M., et al., COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 2010. 468(7326): p. 968-72.
88. Villanueva, J., et al., Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010. 18(6): p. 683-95.
89. Luebker, S.A. and S.A. Koepsell, Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies. Front Oncol, 2019. 9: p. 268.
90. Jazirehi, A.R., et al., Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. Am J Clin Exp Immunol, 2014. 3(1): p. 43-56.
91. Jameson, K.L., et al., IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med, 2013. 19(5): p. 626-630.
92. Girotti, M.R., et al., Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov, 2013. 3(2): p. 158-67.
93. Anastas, J.N., et al., WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest, 2014. 124(7): p. 2877-90.
94. Sandri, S., et al., Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Pharmacol Res, 2016. 111: p. 523-533.
95. Cordaro, F.G., et al., Phenotype characterization of human melanoma cells resistant to dabrafenib. Oncol Rep, 2017. 38(5): p. 2741-2751.
96. Caporali, S., et al., Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol, 2016. 49(3): p. 1164-74.
97. Straussman, R., et al., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012. 487(7408): p. 500-4.
98. Fedorenko, I.V., et al., BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol, 2015. 135(12): p. 3115-3124.
99. Frame, M.C. and A. Serrels, FAK to the rescue: activated stroma promotes a "safe haven" for BRAF-mutant melanoma cells by inducing FAK signaling. Cancer Cell, 2015. 27(4): p. 429-31.
100. Hirata, E., et al., Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell, 2015. 27(4): p. 574-88.
101. Wang, T., et al., BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res, 2015. 21(7): p. 1652-64.
102. Bai, R., et al., Mechanisms of Cancer Resistance to Immunotherapy. Front Oncol, 2020. 10: p. 1290.
103. Zaretsky, J.M., et al., Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med, 2016. 375(9): p. 819-29.
104. Shin, D.S., et al., Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov, 2017. 7(2): p. 188-201.
105. Sade-Feldman, M., et al., Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun, 2017. 8(1): p. 1136.
106. Gao, J., et al., Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell, 2016. 167(2): p. 397-404 e9.
107. Manguso, R.T., et al., In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature, 2017. 547(7664): p. 413-418.
108. Patel, S.J., et al., Identification of essential genes for cancer immunotherapy. Nature, 2017. 548(7669): p. 537-542.
109. Pan, D., et al., A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science, 2018. 359(6377): p. 770-775.
110. Li, M., et al., USP22 deficiency in melanoma mediates resistance to T cells through IFNgamma-JAK1-STAT1 signal axis. Mol Ther, 2021. 29(6): p. 2108-2120.
111. Peng, W., et al., Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov, 2016. 6(2): p. 202-16.
112. Trujillo, J.A., et al., Secondary resistance to immunotherapy associated with beta-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer, 2019. 7(1): p. 295.
113. Liu, D., et al., Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med, 2021. 27(6): p. 985-992.
114. Spranger, S., R. Bao, and T.F. Gajewski, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature, 2015. 523(7559): p. 231-5.
115. Finlay, B.B., et al., Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol, 2020. 20(9): p. 522-528.
116. Gopalakrishnan, V., et al., Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2018. 359(6371): p. 97-103.
117. Davar, D., et al., Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science, 2021. 371(6529): p. 595-602.
118. Garzon, R., et al., MicroRNA expression and function in cancer. Trends Mol Med, 2006. 12(12): p. 580-7.
119. Lin, S. and R.I. Gregory, MicroRNA biogenesis pathways in cancer. Nat Rev Cancer, 2015. 15(6): p. 321-33.
120. Rupaimoole, R. and F.J. Slack, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov, 2017. 16(3): p. 203-222.
121. Winter, J., et al., Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol, 2009. 11(3): p. 228-34.
122. Treiber, T., N. Treiber, and G. Meister, Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol, 2019. 20(1): p. 5-20.
123. Howell, P.M., Jr., et al., MicroRNA in Melanoma. Ochsner J, 2010. 10(2): p. 83-92.
124. Mueller, D.W., M. Rehli, and A.K. Bosserhoff, miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol, 2009. 129(7): p. 1740-51.
125. Aksenenko, M., et al., Differences in microRNA expression between melanoma and healthy adjacent skin. BMC Dermatol, 2019. 19(1): p. 1.
126. Ghafouri-Fard, S., M. Gholipour, and M. Taheri, MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets. Front Oncol, 2021. 11: p. 608987.
127. Bortolin-Cavaille, M.L., et al., C19MC microRNAs are processed from introns of large Pol-II, non-protein-coding transcripts. Nucleic Acids Res, 2009. 37(10): p. 3464-73.
128. Liu, S.M., et al., miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. Oncotarget, 2014. 5(19): p. 9444-59.
129. Chen, L., et al., The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis, 2012. 33(11): p. 2276-82.
130. Liu, G.H., et al., MicroRNA-524-5p suppresses the growth and invasive abilities of gastric cancer cells. Oncol Lett, 2016. 11(3): p. 1926-1932.
131. Zhen, W., et al., MicroRNA-524-5p Functions as a Tumor Suppressor in a Human Pituitary Tumor-Derived Cell Line. Horm Metab Res, 2017. 49(7): p. 550-557.
132. Xu, T., et al., MicroRNA-524 inhibits the progress of glioma via the direct targeting of NCF2. Am J Transl Res, 2019. 11(3): p. 1605-1615.
133. Zhu, C.Y., F.Q. Meng, and J. Liu, MicroRNA-524-5p suppresses cell proliferation and promotes cell apoptosis in gastric cancer by regulating CASP3. Eur Rev Med Pharmacol Sci, 2019. 23(18): p. 7968-7977.
134. Wang, J., et al., Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. Oncotarget, 2017. 8(1): p. 574-582.
135. Feng, H., et al., LncRNA TTN-AS1 Regulates miR-524-5p and RRM2 to Promote Breast Cancer Progression. Onco Targets Ther, 2020. 13: p. 4799-4811.
136. Li, X., et al., miR-524-5p inhibits angiogenesis through targeting WNK1 in colon cancer cells. Am J Physiol Gastrointest Liver Physiol, 2020. 318(4): p. G827-G839.
137. Liu, H., et al., MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways. J Cell Physiol, 2019. 234(10): p. 18382-18391.
138. Liu, S., et al., Long noncoding RNA TUG1 regulates the development of oral squamous cell carcinoma through sponging miR-524-5p to mediate DLX1 expression as a competitive endogenous RNA. J Cell Physiol, 2019. 234(11): p. 20206-20216.
139. Chen, H., C. Cheng, and S. Gao, microRNA-524-5p inhibits proliferation and induces cell cycle arrest of osteosarcoma cells via targeting CDK6. Biochem Biophys Res Commun, 2020. 530(3): p. 566-573.
140. Lu, L., et al., Exosomal lncRNA TUG1 from cancer-associated fibroblasts promotes liver cancer cell migration, invasion, and glycolysis by regulating the miR-524-5p/SIX1 axis. Cell Mol Biol Lett, 2022. 27(1): p. 17.
141. Jin, T., Y. Zhang, and T. Zhang, MiR-524-5p Suppresses Migration, Invasion, and EMT Progression in Breast Cancer Cells Through Targeting FSTL1. Cancer Biother Radiopharm, 2020. 35(10): p. 789-801.
142. Bai, X., et al., Long noncoding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR5245p/HMGA2 axis. Mol Med Rep, 2021. 23(6).
143. Zheng, L., et al., MicroRNA5245p regulates the proliferation and invasion of HTR8/SVneo trophoblasts by targeting NUMB in the Notch signaling pathway. Mol Med Rep, 2021. 23(6).
144. Chen, L., et al., Downregulated miR-524-5p Participates in the Tumor Microenvironment of Ameloblastoma by Targeting the Interleukin-33 (IL-33)/Suppression of Tumorigenicity 2 (ST2) Axis. Med Sci Monit, 2020. 26: p. e921863.
145. Nguyen, P.N.N., et al., miR-524-5p of the primate-specific C19MC miRNA cluster targets TP53IPN1- and EMT-associated genes to regulate cellular reprogramming. Stem Cell Res Ther, 2017. 8(1): p. 214.
146. Bertoli, G., et al., MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration. Breast Cancer Res Treat, 2017. 161(3): p. 605-616.
147. Liu, D., et al., MicroRNA-567 inhibits cell proliferation, migration and invasion by targeting FGF5 in osteosarcoma. EXCLI J, 2018. 17: p. 102-112.
148. Zhang, F., et al., A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer. EBioMedicine, 2019. 44: p. 311-321.
149. Han, M., et al., Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death Dis, 2020. 11(1): p. 43.
150. Elkady, M.A., et al., MicroRNA-567 inhibits cell proliferation and induces cell apoptosis in A549 NSCLC cells by regulating cyclin-dependent kinase 8. Saudi J Biol Sci, 2021. 28(4): p. 2581-2590.
151. Yu, C., et al., Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR-567/PTPRG regulatory pathway. Cell Prolif, 2019. 52(3): p. e12610.
152. Yu, R., J. Yao, and Y. Ren, A novel circRNA, circNUP98, a potential biomarker, acted as an oncogene via the miR-567/ PRDX3 axis in renal cell carcinoma. J Cell Mol Med, 2020. 24(17): p. 10177-10188.
153. Jin, L., et al., Circ_0030998 promotes tumor proliferation and angiogenesis by sponging miR-567 to regulate VEGFA in colorectal cancer. Cell Death Discov, 2021. 7(1): p. 160.
154. Li, Z., et al., Long non-coding RNA CERS6-AS1 plays a prognostic role in promoting the progression of gastric cancer. Bioengineered, 2021. 12(2): p. 12931-12939.
155. Camisaschi, C., et al., Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment. Expert Rev Mol Diagn, 2014. 14(6): p. 643-6.
156. Falcone, I., et al., Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers (Basel), 2020. 12(10).
157. Kluger, H.M., et al., Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res, 2015. 21(13): p. 3052-60.
158. Lee, N., et al., Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology, 2016. 48(2): p. 177-87.
159. Mantovani, A., et al., Cancer-related inflammation. Nature, 2008. 454(7203): p. 436-44.
160. Fu, Q., et al., Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology, 2019. 8(7): p. 1593806.
161. de Moll, E.H., et al., Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunol Immunother, 2015. 64(9): p. 1193-203.
162. Solinas, G., et al., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol, 2009. 86(5): p. 1065-73.
163. Murdoch, C., et al., The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer, 2008. 8(8): p. 618-31.
164. Umemura, N., et al., Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol, 2008. 83(5): p. 1136-44.
165. Fujimura, T., et al., Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer. Front Oncol, 2018. 8: p. 3.
166. Kessenbrock, K., V. Plaks, and Z. Werb, Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010. 141(1): p. 52-67.
167. Bernengo, M.G., et al., Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. Melanoma Res, 2000. 10(1): p. 55-65.
168. Makitie, T., et al., Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci, 2001. 42(7): p. 1414-21.
169. Ojalvo, L.S., et al., Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol, 2010. 184(2): p. 702-12.
170. Lissbrant, I.F., et al., Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol, 2000. 17(3): p. 445-51.
171. Hanada, T., et al., Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol, 2000. 7(7): p. 263-9.
172. Jensen, T.O., et al., Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol, 2009. 27(20): p. 3330-7.
173. Zaidi, M.R., et al., Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. Nature, 2011. 469(7331): p. 548-53.
174. Smith, M.P., et al., The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov, 2014. 4(10): p. 1214-1229.
175. Bolat, F., et al., Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res, 2006. 25(3): p. 365-72.
176. Luo, Y., et al., Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest, 2006. 116(8): p. 2132-2141.
177. Liu, H., et al., NFAT1 enhances the effects of tumor-associated macrophages on promoting malignant melanoma growth and metastasis. Biosci Rep, 2018. 38(6).
178. Di Martile, M., et al., Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. J Immunother Cancer, 2020. 8(1).
179. Andrade, L.N.S., et al., Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy. Sci Rep, 2019. 9(1): p. 14482.
180. Marton, A., et al., Melanoma cell-derived exosomes alter macrophage and dendritic cell functions in vitro. Immunol Lett, 2012. 148(1): p. 34-8.
181. Bardi, G.T., M.A. Smith, and J.L. Hood, Melanoma exosomes promote mixed M1 and M2 macrophage polarization. Cytokine, 2018. 105: p. 63-72.
182. Huber, V., et al., Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J Clin Invest, 2018. 128(12): p. 5505-5516.
183. Liu, Y., et al., MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol, 2012. 188(11): p. 5500-10.
184. Gaziel-Sovran, A., et al., miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell, 2011. 20(1): p. 104-18.
185. Huffaker, T.B., et al., Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep, 2012. 2(6): p. 1697-709.
186. Lin, R., et al., Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest, 2014. 124(12): p. 5352-67.
187. Li, Q., et al., miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget, 2016. 7(33): p. 53735-53750.
188. Heinemann, A., et al., Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res, 2012. 72(2): p. 460-71.
189. Lazaridou, M.F., et al., Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. Oncoimmunology, 2020. 9(1): p. 1774323.
190. Liang, X., et al., MicroRNA-22 impairs anti-tumor ability of dendritic cells by targeting p38. PLoS One, 2015. 10(3): p. e0121510.
191. Liang, X., et al., miR-128 enhances dendritic cell-mediated anti-tumor immunity via targeting of p38. Mol Med Rep, 2017. 16(2): p. 1307-1313.
192. Cordeiro, B., et al., MicroRNA-9 Fine-Tunes Dendritic Cell Function by Suppressing Negative Regulators in a Cell-Type-Specific Manner. Cell Rep, 2020. 31(5): p. 107585.
193. Li, Q., et al., MiR-21/Smad 7 signaling determines TGF-beta1-induced CAF formation. Sci Rep, 2013. 3: p. 2038.
194. Dror, S., et al., Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol, 2016. 18(9): p. 1006-17.
195. Sahraei, M., et al., Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest, 2019. 129(12): p. 5518-5536.
196. Arts, N., et al., microRNA-155, induced by interleukin-1ss, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells. PLoS One, 2015. 10(4): p. e0122517.
197. Jing, X., et al., Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer, 2019. 18(1): p. 157.
198. Brustugun, O.T., Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung. Semin Radiat Oncol, 2015. 25(2): p. 87-92.
199. Tittarelli, A., et al., Hypoxic Melanoma Cells Deliver microRNAs to Dendritic Cells and Cytotoxic T Lymphocytes through Connexin-43 Channels. Int J Mol Sci, 2020. 21(20).
200. Galore-Haskel, G., et al., A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget, 2015. 6(30): p. 28999-9015.
201. Tengda, L., et al., Serum exosomal microRNAs as potent circulating biomarkers for melanoma. Melanoma Res, 2018. 28(4): p. 295-303.
202. Nakahara, S., et al., MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma. J Dermatol Sci, 2020. 97(1): p. 77-79.
203. Johnson, D.B., et al., Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer, 2015. 51(18): p. 2792-9.
204. Nguyen, M.T., et al., miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma. Neoplasia, 2020. 22(12): p. 789-799.
205. Liu, S.M., et al., miR-596 Modulates Melanoma Growth by Regulating Cell Survival and Death. J Invest Dermatol, 2018. 138(4): p. 911-921.
206. Sun, X., et al., miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget, 2016. 7(33): p. 53558-53570.
207. Liu, S., et al., miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell Melanoma Res, 2015. 28(4): p. 431-41.
208. Koetz-Ploch, L., et al., MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res, 2017. 30(3): p. 328-338.
209. Diaz-Martinez, M., et al., miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Res, 2018. 78(4): p. 1017-1030.
210. Lee, B., et al., MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF(V600E)-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance. J Invest Dermatol, 2021. 141(2): p. 385-394.
211. Grzywa, T.M., et al., miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma. PLoS One, 2020. 15(6): p. e0234707.
212. Kim, J.H., J.H. Ahn, and M. Lee, Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF. Cancer Res Treat, 2017. 49(4): p. 947-959.
213. Choe, M.H., et al., miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP. Cell Death Dis, 2018. 9(6): p. 640.
214. Ji, Z., et al., MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol, 2015. 135(7): p. 1863-1872.
215. He, B., et al., miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci, 2020. 16(14): p. 2628-2647.
216. Sanmamed, M.F., et al., Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem, 2015. 61(1): p. 297-304.
217. Gray, E.S., et al., Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015. 6(39): p. 42008-18.
218. Salemi, R., et al., MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA. Front Pharmacol, 2018. 9: p. 856.
219. Hoek, K.S., et al., In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res, 2008. 68(3): p. 650-6.
220. Arozarena, I. and C. Wellbrock, Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer, 2019. 19(7): p. 377-391.
221. Faiao-Flores, F., et al., Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. Oncogene, 2017. 36(13): p. 1849-1861.
222. Johannessen, C.M., et al., A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature, 2013. 504(7478): p. 138-42.
223. Kawakami, A. and D.E. Fisher, The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest, 2017. 97(6): p. 649-656.
224. Slattery, M.J. and C. Dong, Neutrophils influence melanoma adhesion and migration under flow conditions. Int J Cancer, 2003. 106(5): p. 713-22.
225. Payne, A.S. and L.A. Cornelius, The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol, 2002. 118(6): p. 915-22.
226. Markiewski, M.M. and J.D. Lambris, The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol, 2007. 171(3): p. 715-27.
227. Nabizadeh, J.A., et al., The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses. J Immunol, 2016. 196(11): p. 4783-92.
228. Pencheva, N., et al., Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell, 2014. 156(5): p. 986-1001.
229. Bronkhorst, I.H., et al., Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci, 2011. 52(2): p. 643-50.
230. Falleni, M., et al., M1 and M2 macrophages′ clinicopathological significance in cutaneous melanoma. Melanoma Res, 2017. 27(3): p. 200-210.
231. Pieniazek, M., R. Matkowski, and P. Donizy, Macrophages in skin melanoma-the key element in melanomagenesis. Oncol Lett, 2018. 15(4): p. 5399-5404.
232. Gazzaniga, S., et al., Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol, 2007. 127(8): p. 2031-41.
233. Halin, S., et al., Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia, 2009. 11(2): p. 177-86.
234. Kimura, Y.N., et al., Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci, 2007. 98(12): p. 2009-18.
235. Robinson-Smith, T.M., et al., Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res, 2007. 67(12): p. 5708-16.
236. Zeisberger, S.M., et al., Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer, 2006. 95(3): p. 272-81.
237. Tang, Z., et al., GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017. 45(W1): p. W98-W102.
238. Li, C., M. Levin, and D.L. Kaplan, Bioelectric modulation of macrophage polarization. Sci Rep, 2016. 6: p. 21044.
239. Wang, T., et al., Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res, 2012. 25(4): p. 493-505.
240. Yuen, J.S. and V.M. Macaulay, Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets, 2008. 12(5): p. 589-603.
241. Karasic, T.B., T.K. Hei, and V.N. Ivanov, Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res, 2010. 316(12): p. 1994-2007.
242. Yeh, A.H., E.A. Bohula, and V.M. Macaulay, Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene, 2006. 25(50): p. 6574-81.
243. Xin, H., et al., Suppression of IGF1R in Melanoma Cells by an Adenovirus-Mediated One-Step Knockdown System. Mol Ther Nucleic Acids, 2018. 12: p. 861-871.
244. Rouaud, F., et al., E2F1 inhibition mediates cell death of metastatic melanoma. Cell Death Dis, 2018. 9(5): p. 527.
245. Alla, V., et al., E2F1 in melanoma progression and metastasis. J Natl Cancer Inst, 2010. 102(2): p. 127-33.
246. Meng, P., et al., Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness. Mol Carcinog, 2019. 58(9): p. 1701-1710.
247. Qian, X., et al., CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients. Biomed Pharmacother, 2015. 74: p. 222-7.
248. Lei, C.Y., et al., The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder cancer. Urol Oncol, 2016. 34(5): p. 237 e1-10.
249. Ajona, D., et al., Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst, 2013. 105(18): p. 1385-93.
250. Maher, S.G., et al., Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg, 2011. 254(5): p. 809-16; discussion 816-7.
251. Alavi, S., et al., Interferon Signaling Is Frequently Downregulated in Melanoma. Front Immunol, 2018. 9: p. 1414.
252. Luke, J.J., et al., Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol, 2017. 14(8): p. 463-482.
253. Grasso, C.S., et al., Conserved Interferon-gamma Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020. 38(4): p. 500-515 e3.
254. Yuan, J., et al., The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol, 2020. 13(1): p. 113.
255. Couts, K.L., et al., Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene, 2013. 32(15): p. 1959-70.
256. Strub, T., R. Ballotti, and C. Bertolotto, The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies". Theranostics, 2020. 10(4): p. 1777-1797.
257. Lee, J.J., G.F. Murphy, and C.G. Lian, Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest, 2014. 94(8): p. 822-38.
258. Moran, B., et al., Epigenetics of malignant melanoma. Semin Cancer Biol, 2018. 51: p. 80-88.
259. Schinke, C., et al., Aberrant DNA methylation in malignant melanoma. Melanoma Res, 2010. 20(4): p. 253-65.
260. Chen, C., et al., Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol, 2013. 8: p. 199.
261. Sullivan, L., et al., IGFBP7 promoter methylation and gene expression analysis in prostate cancer. J Urol, 2012. 188(4): p. 1354-60.
262. Liu, Y., et al., Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia, 2006. 8(1): p. 46-51.
263. Jia, H., et al., MicroRNA-10a is down-regulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells. PLoS One, 2014. 9(1): p. e88057.
264. Kim, K., et al., Epigenetic regulation of microRNA-10b and targeting of oncogenic MAPRE1 in gastric cancer. Epigenetics, 2011. 6(6): p. 740-51.
265. Balaguer, F., et al., Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res, 2010. 70(16): p. 6609-18.
266. Kozaki, K., et al., Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res, 2008. 68(7): p. 2094-105.
267. Namlos, H.M., et al., miR-486-5p expression is regulated by DNA methylation in osteosarcoma. BMC Genomics, 2022. 23(1): p. 142.
268. Datta, J., et al., Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res, 2008. 68(13): p. 5049-58.
269. Ayala-Ortega, E., et al., Epigenetic silencing of miR-181c by DNA methylation in glioblastoma cell lines. BMC Cancer, 2016. 16: p. 226.
270. Asangani, I.A., et al., Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget, 2012. 3(9): p. 1011-25.
271. Dar, A.A., et al., The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst, 2013. 105(6): p. 433-42.
272. Micevic, G., N. Theodosakis, and M. Bosenberg, Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics, 2017. 9: p. 34.
273. Wang, Y., et al., The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett, 2018. 415: p. 117-128.
274. Curtale, G., M. Rubino, and M. Locati, MicroRNAs as Molecular Switches in Macrophage Activation. Front Immunol, 2019. 10: p. 799.
275. Wang, Z., et al., miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer. Sci Rep, 2016. 6: p. 25602.
276. Boucher, A., et al., The miR-23a approximately 27a approximately 24-2 microRNA Cluster Promotes Inflammatory Polarization of Macrophages. J Immunol, 2021. 206(3): p. 540-553.
277. Cai, X., et al., Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol, 2012. 4(5): p. 341-3.
278. Ying, H., et al., MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway. J Immunol, 2015. 194(3): p. 1239-51.
279. Chaudhuri, A.A., et al., MicroRNA-125b potentiates macrophage activation. J Immunol, 2011. 187(10): p. 5062-8.
280. Li, D., et al., MiR-146a modulates macrophage polarization in systemic juvenile idiopathic arthritis by targeting INHBA. Mol Immunol, 2016. 77: p. 205-12.
281. Cobos Jimenez, V., et al., Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages. Physiol Genomics, 2014. 46(3): p. 91-103.
282. Liu, G. and E. Abraham, MicroRNAs in immune response and macrophage polarization. Arterioscler Thromb Vasc Biol, 2013. 33(2): p. 170-7.
283. Xun, J., et al., Cancer-derived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B. Theranostics, 2021. 11(14): p. 6847-6859.
284. Gerloff, D., et al., Melanoma-Derived Exosomal miR-125b-5p Educates Tumor Associated Macrophages (TAMs) by Targeting Lysosomal Acid Lipase A (LIPA). Cancers (Basel), 2020. 12(2).
285. Ibrahim, A.F., et al., MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res, 2011. 71(15): p. 5214-24.
286. Pecot, C.V., et al., Tumour angiogenesis regulation by the miR-200 family. Nat Commun, 2013. 4: p. 2427.
287. Cortez, M.A., et al., Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther, 2014. 22(8): p. 1494-1503. |